264 Million Reasons Psychedelic Stocks Have More Room to Grow
Finding a treatment for those 264 million people suffering from depression are what its all about.
- Finding a treatment for those 264 million people suffering from depression are what its all about.
- OTC Stock Review introduced a large number of investors to the psychedelic sector with an article on Seeking Alpha March 6, 2020 titled " Psychedelic Medicine Stocks Capture the Attention of Investors ."
- Almost a year later we are still focusing on psychedelic stocks and the potential treatments for depression and improving mental health.
- MindMed also offers the broadest and most diversified pipeline of psychedelic drugs in clinical development and R&D.